Low-dose cisplatin plus 5-fluorouracil with radiotherapy for unresectable upper and hilar bile duct carcinoma

Akira Oda, Y. Katayose, Toshiki Rikiyama, Masaya Oikawa, Kuniharu Yamamoto, Hiroki Hayashi, Michiaki Unno

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

We report herein the value of a combined treatment modality for bile duct cancer (intraluminal brachytherapy: ILBT+extrabeam radiation therapy+chemotherapy+expandable metallic biliary stent), employed for cases in which excision of the upper and the hilar bile duct cancer was not possible. The combined treatment modality group did not attain a two-year survival rate according to the Kaplan Meier method. They were not able to surpass the treatment results of the excision group which ended in radical cure level of C. Moreover, with the combined modality treatment, the addition of radiation therapy significantly improved the cumulative survival rate. In conclusion, the first choice of treatment for the upper and the hilar bile duct cancer is excision, and it is necessary to thoroughly examine the possibility of excision. Additionally, to surpass the treatment results of the excision group that ended in a radical cure level of C, it is necessary to include radiation therapy and chemotherapy using new anti-cancer drugs in a combined treatment modality.

Original languageEnglish
Pages (from-to)1615-1617
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume32
Issue number11
Publication statusPublished - 2005 Oct

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Low-dose cisplatin plus 5-fluorouracil with radiotherapy for unresectable upper and hilar bile duct carcinoma'. Together they form a unique fingerprint.

Cite this